Benchmark Maintains Buy on Nutex Health, Lowers Price Target to $1

Benzinga · 01/25 15:38
Benchmark analyst Bill Sutherland maintains Nutex Health (NASDAQ:NUTX) with a Buy and lowers the price target from $1.5 to $1.